On June 1, 2010
Safety Concerns Unlikely to Delay FDA Approval of Novartis’ MS Drug Gilenia
Novartis AG (NVS) said the FDA extended the review period for its investigational multiple sclerosis (MS) drug Gilenia by three months. Given the unexplained “refuse-to-file” letter received by a competitor last December from U.S. regulators for their own experimental oral
…
0 Comments